Pharmacokinetics and metabolism of [¹⁴C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

References

• Ahrén B. (2009). Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin–diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 23:487–498.
   PubMed Web of Science ®Google Scholar
• Atack JR, Yu QS, Soncrant TT, Brossi A, Rapoport SI. (1989). Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases. J Pharmacol Exp Ther 249:194–202.
   PubMed Web of Science ®Google Scholar
• Brandt I, Joossens J, Chen X, Maes MB, Scharpé S, De Meester I, Lambeir AM. (2005). Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 70:134–143.
   PubMed Web of Science ®Google Scholar
• Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. (2001). Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277–1286.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Lee K, Kruh GD. (2001). Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276:33747–33754.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. (1995a). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–1131.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. (1995b). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705.
   PubMed Web of Science ®Google Scholar
• Duez H, Cariou B, Staels B. (2012). DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 83:823–832.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Halimi S, Schweizer A, Minic B, Foley J, Dejager S. (2008). Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 4:481–492.
   PubMedGoogle Scholar
• Hatfield MJ, Tsurkan L, Garrett M, Shaver TM, Hyatt JL, Edwards CC, Hicks LD, Potter PM. (2011). Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 81:24–31.
   PubMed Web of Science ®Google Scholar
• Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, Sugiyama Y. (2000). Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther 292:265–270.
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. (2007). Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 9:153–165.
   PubMed Web of Science ®Google Scholar
• Islinger F, Gekle M, Wright SH. (2001). Interaction of 2,3-dimercapto-1-propane sulfonate with the human organic anion transporter hOAT1. J Pharmacol Exp Ther 299:741–747.
   PubMed Web of Science ®Google Scholar
• Jbilo O, Bartels CF, Chatonnet A, Toutant JP, Lockridge O. (1994). Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32:1445–1457.
   PubMed Web of Science ®Google Scholar
• Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, Yasuda Y, Yoshikawa A, Hayashi Y, Makino M, Takeda M, Mirensha Y, Kakigami T. (2011). Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 19:7221–7227.
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. (2005). Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379–386.
   PubMedGoogle Scholar
• Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S. (1989). Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902–905.
   PubMed Web of Science ®Google Scholar
• Lambeir AM, Durinx C, Scharpé S, De Meester I. (2003). Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40:209–294.
   PubMed Web of Science ®Google Scholar
• Masaki K, Hashimoto M, Imai T. (2007). Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum. Drug Metab Dispos 35:1089–1095.
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. (1993). Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829–835.
   PubMedGoogle Scholar
• Mest HJ, Mentlein R. (2005). Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48:616–620.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492–498.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307.
   PubMed Web of Science ®Google Scholar
• Orskov C, Holst JJ, Nielsen OV. (1988). Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009–2013.
   PubMed Web of Science ®Google Scholar
• Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. (2004). Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141:929–937.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. (2003). Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63:1165–1184.
   PubMed Web of Science ®Google Scholar
• Sharma MD. (2010). Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag 6:233–237.
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4–14.
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, van Haeften TW. (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346.
   PubMed Web of Science ®Google Scholar
• Sunami Y, Yoshioka N, Hayashi I, Ishida T. (2007). Safety, tolerability, pharmacokinetics and pharmacodynamics of sk-0403, a novel dpp-iv inhibitor, in healthy japanese subjects. American Diabetes Association 67th Scientific Session, Chicago, IL, Jun. 22–26, Poster 0482-P [Online]. Available at: http://professional.diabetes.org/Content/Posters/2007/p0482-P.pdf (Accessed on 13 September 2012).
   Google Scholar
• Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R. (1992). Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840–845.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Agersø H, Krarup T, Holst JJ. (2003). Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220–224.
   PubMed Web of Science ®Google Scholar
• Volk EL, Schneider E. (2003). Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538–5543.
   PubMed Web of Science ®Google Scholar
• Wählby S, Engström L. (1968). Studies on Streptomyces griseus protease. II. The amino acid sequence around the reactive serine residue of DFP-sensitive components with esterase activity. Biochim Biophys Acta 151:402–408.
   Google Scholar
• Zerilli T, Pyon EY. (2007). Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 29:2614–2634.
   PubMed Web of Science ®Google Scholar